A recent clinical study published in the journal Ophthalmology brings mixed news to the practice of glaucoma care. According to the data, the current standard practice of applanation tonometry for measuring intraocular pressure (IOP) is insufficient in providing an accurate representation of an individual’s real IOP over time. The good news is that the continual monitoring via Implandata’s EYEMATE™ System enables accurate IOP measurement and improved glaucoma care.
The current standard practice is to measure glaucoma patients’ IOP in a doctor’s office, typically four to six times per year. For patients, this means a high risk of undetected disease progression, which can result in vision loss. The findings demonstrate that the EYEMATE™ System enables safe, reliable, continual IOP monitoring, without necessitating regular office visits. EYEMATE enables patients and their doctors to be informed in real-time of disease progression, which means the therapy is adjusted without delay – before eyesight is permanently lost.
"Our findings show that occasional IOP measurements, as are currently done in clinical practice, poorly reflect actual IOP behavior in patients. These data underline the importance of continual IOP monitoring for better management of glaucoma care,” explained Dr. Kaweh Mansouri, MD, MPH, lead author of the study and ophthalmologist at Clinique de Montchoisi Lausanne/Switzerland.
"Our findings have important implications both for clinical glaucoma management as well as clinical trials. Although results from a single session of IOP monitoring have limited benefit for predicting IOP behavior, the current assumption of conserved IOP patterns over weeks and months is used at present in glaucoma management and underlies numerous glaucoma medication trials. The evidence for this premise, however, has always been weak, since few studies previously have addressed this issue,” added Dr. Robert N. Weinreb MD, Chair and Distinguished Professor of Ophthalmology at the University of California, San Diego.
Learn more about the EYEMATE™ System and Implandata Ophthalmic Products GmbH.
Full press release: https://www.b3cnewswire.com/202007272099/digital-health-clinical-study-published-in-ophthalmology-demonstrates-implandata-s-eyemate-system-benefits-glaucoma-patients.html